Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis

References

• Dayyani F, Etzel CJ, Liu M, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15
   PubMedGoogle Scholar
• De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124(7):1626-36
   PubMed Web of Science ®Google Scholar
• Miralles-Guri C, Bruni L, Cubilla AL, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009;62(10):870-8
   PubMed Web of Science ®Google Scholar
• Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439
   PubMedGoogle Scholar
• Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 2013;8(7):e69238
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364(5):401-11
   PubMed Web of Science ®Google Scholar
• Recommendations on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60(50):1705-8
   PubMedGoogle Scholar
• Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29(49):9171-6
   Google Scholar
• Update On Human Papillomavirus (HPV) Vaccines. Public Health Agency of Canada. Canada Communicable Disease Report, Volume 38, January 2012. Available from: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php [Last accessed October 2013]
   Google Scholar
• Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program. Australian Department of Health. Available from: www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv [Last accessed October 2013]
   Google Scholar
• Rössler L, Reich O, Horvat R, et al. Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. Wien Klin Wochenschr 2013;125(19-20):591-9
   Google Scholar
• Statistik Austria. Anzahl der unterschiedlichen medizinischen Einzelleistungen bei Spitalentlassungen 2009 und 2010. Available from: www.statistik.at/web_de/statistiken/gesundheit/stationaere_aufenthalte/medizinische_leistungen/index.html [Last accessed October 2013]
   Google Scholar
• Georgousakis M, Jayasinghe S, Brotherton J, et al. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012;12(8):627-34
   PubMedGoogle Scholar
• La Torre G, de Waure C, Chiaradia G, et al. Guidance for future HTA applications to vaccines: the HPV lesson. Hum Vaccin 2011;7(9):900-4
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28(42):6858-67
   PubMed Web of Science ®Google Scholar
• Walter E, Zehetmayr S. Guidelines zur gesundheitsökonomischen Evaluation – Konsenspapier; April 2006. Available from: www.ispor.org/peguidelines/source/Guidelines_%C3%96sterreich.pdf [Last accessed October 2013]
   Google Scholar
• Statistik Austria. Bevölkerung im Jahresdurchschnitt nach Alter und Geschlecht. Available from: www.statistik.at/web_de/statistiken/soziales/gender-statistik/demographie/043902.html [Last accessed October 2013]
   Google Scholar
• Erens B, McManus S, Prescott A, et al. National Survey of Sexual Attitudes and Lifestyles II. National Center for Social Research; April 2003. Available from: www.natsal.ac.uk/media/821936/reference_tables_and_summary_report.pdf [Last accessed October 2013]
   Google Scholar
• Kundi M. Health economics of HPV vaccination in Austria. Cost-effectiveness of vaccinating 12 year old girls. Value Health 2009;12(7):A274
   Google Scholar
• Zechmeister I, Blasio BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009;27(37):5133-41
   PubMed Web of Science ®Google Scholar
• Ökonomische Evaluation der Impfung gegen humane Papillomviren (HPV Impfung) in Österreich. Ludwig Boltzmann Institut, Wien. 2007. Available from: http://eprints.hta.lbg.ac.at/760/2/HTA-Projektbericht_009.pdf
   Google Scholar
• Vutuc C, Haidinger G, Waldhoer T, et al. Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria. Wien Klin Wochenschr 1999;111(9):354-9
   Google Scholar
• Statistik Austria. Gebärmutterhals. Available from: www.statistik.at/web_de/statistiken/gesundheit/krebserkrankungen/gebaermutterhals/index.html [Last accessed October 2013]
   Google Scholar
• Hartwig S, Syrjanen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012;12:30
   PubMed Web of Science ®Google Scholar
• Kraut AA, Schink T, Schulze-Rath R, et al. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010;10:360
   PubMed Web of Science ®Google Scholar
• Statistik Austria. Bevölkerung im Jahresdurchschnitt nach Alter und Geschlecht. Available from: www.statistik.at/web_de/statistiken/soziales/gender-statistik/demographie/043902.html [Last accessed October 2013]
   Google Scholar
• Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev 2012;2(1):19
   PubMedGoogle Scholar
• Robert Koch Institute and Association of Population-based Cancer Registries in Germany. editors. Cancer in Germany, 2003–2004. Incidence and Trends. 6th edition. Robert Koch Institute, Berlin; 2008. Available from: www.ekr.med.uni-erlangen.de/GEKID/Doc/kid2008_english.pdf [Last accessed October 2013]
   Google Scholar
• Statistik Austria (2011). Todesursachenstatistik – Krebsstatistik. Available from: www.statistik.at/ [Last accessed October 2013]
   Google Scholar
• Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100(4):261-9
   PubMedGoogle Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35
   PubMed Web of Science ®Google Scholar
• Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27(12):1992-8
   PubMed Web of Science ®Google Scholar
• Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011;100(1):49-55
   PubMed Web of Science ®Google Scholar
• Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22(5):1071-7
   PubMed Web of Science ®Google Scholar
• Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28(27):4142-8
   PubMed Web of Science ®Google Scholar
• Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775
   PubMed Web of Science ®Google Scholar
• Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine 2013;31(37):3863-71
   PubMed Web of Science ®Google Scholar
• Hampl M, Huppertz E, Schulz-Holstege O, et al. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infect Dis 2011;11:73
   PubMed Web of Science ®Google Scholar
• Hillemanns P, Petry KU, Largeron N, et al. Cost effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health 2009;17:77-86
   Google Scholar
• OECD. Gross domestic product (GDP): GDP Deflator. Available from: http://stats.oecd.org/Index.aspx?DatasetCode=DACDEFL [Last accessed October 2013]
   Google Scholar
• Bresse X, Adam M, Largeron N, et al. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France. Hum Vaccin Immunother 2013;9(4):823-33
   PubMed Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making 2012;32(5):712-21
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):F12-23
   PubMed Web of Science ®Google Scholar
• EMA Public Assessment Report for GARDASIL. 2011. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01%20ac058001d124 [Last accessed October 2013]
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Guidance for the introduction of HPV vaccines in EU countries – An update. Stockholm, Sweden; July 2012. Available from: http://ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.pdf [Last accessed October 2013]
   Google Scholar
• Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004;16(8):530-5
   PubMed Web of Science ®Google Scholar
• Logemann JA, Pauloski BR, Rademaker AW, Colangelo LA. Speech and swallowing rehabilitation for head and neck cancer patients. Oncology (Williston Park) 1997;11(5):651-6. 659; discussion 659, 663-4
   Google Scholar
• Murphy BA, Gilbert J, Ridner SH. Systemic and global toxicities of head and neck treatment. Expert Rev Anticancer Ther 2007;7(7):1043-53
   PubMed Web of Science ®Google Scholar
• Rossari JR, Vora T, Gil T. Advances in penile cancer management. Curr Opin Oncol 2010;22(3):226-35
   Google Scholar
• Abendstein H, Nordgren M, Boysen M, et al. Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope 2005;115(12):2183-92
   PubMed Web of Science ®Google Scholar
• Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, de Bree R. Employment and return to work in head and neck cancer survivors. Oral Oncol 2010;46(1):56-60
   Google Scholar
• Burchell AN, Tellier PP, Hanley J, et al. Human papillomavirus infections among couples in new sexual relationships. Epidemiology 2010;21(1):31-7
   Google Scholar
• Foresta C, Ferlin A, Garolla A. HPV vaccination. What about male specific HPV related diseases? BMJ 2009;339:b4514
   Google Scholar
• Hibbitts S. Should boys receive the human papillomavirus vaccine? Yes. BMJ 2009;339:b4928
   Google Scholar
• Hull SC, Caplan AL. The case for vaccinating boys against human papillomavirus. Public Health Genomics 2009;12(5-6):362-7
   PubMed Web of Science ®Google Scholar
• Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer 2004;101(5):1051.1057
   Google Scholar
• Malagon T, Joumier V, Boily MC, et al. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine 2013;31(13):1740-7
   PubMed Web of Science ®Google Scholar
• Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010;26(2):183-91
   Google Scholar
• Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011;129(3):733-41
   PubMed Web of Science ®Google Scholar
• Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125(2):362-6
   PubMed Web of Science ®Google Scholar
• Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012;130(5):1168-73
   PubMed Web of Science ®Google Scholar
• Baldur-Felskov B, Hannibal CG, Munk C, Kjaer SK. Increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in Denmark 1978-2008: a nationwide population-based study. Cancer Causes Control 2012;23(2):273-80
   PubMed Web of Science ®Google Scholar
• Robinson D, Coupland V, Moller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009;100(3):527-31
   PubMed Web of Science ®Google Scholar
• Allal AS, Sprangers MA, Laurencet F, et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999;80(10):1588-94
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22(12):2675-86
   PubMed Web of Science ®Google Scholar
• Bray F, Klint A, Gislum M, et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries. 1964-2003 followed up until the end of 2006. Acta Oncol 2010;49(5):644-54
   PubMed Web of Science ®Google Scholar
• de Graeff A, de Leeuw JR, Ros WJ, et al. Long-term quality of life of patients with head and neck cancer. Laryngoscope 2000;110(1):98-106
   PubMed Web of Science ®Google Scholar
• Jeffreys M, Rachet B, McDowell S, et al. Survival from rectal and anal cancers in England and Wales, 1986-2001. Eur J Cancer 2006;42(10):1434-40
   Google Scholar
• Maddineni SB, Lau MM, Sangar VK. Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer. BMC Urol 2009;9:8
   PubMedGoogle Scholar
• Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11(8):781-9
   PubMed Web of Science ®Google Scholar
• Mortensen GL, Paaske PB. Patients perceive tonsil cancer as a strike at psycho-socially "vital organs". Dan Med J 2012;59(9):A4504
   Google Scholar
• Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009;85(7):508-13
   PubMed Web of Science ®Google Scholar
• Soergel P, Makowski L, Schippert C, et al. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother 2012;8(2):243-51
   PubMed Web of Science ®Google Scholar
• Brisson M, van de Velde N, Franco EL, et al. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011;204(3):372-6
   PubMed Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012;30(Suppl 5):F157-67
   PubMedGoogle Scholar
• Low GM, Attiga YS, Garg G, et al. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States? Viral Immunol 2012;25(3):174-86
   Google Scholar
• Stupiansky NW, Alexander AB, Zimet GD. Human papillomavirus vaccine and men: what are the obstacles and challenges? Curr Opin Infect Dis 2012;25(1):86-91
   PubMed Web of Science ®Google Scholar
• Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10(12):845-52
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gauthier A, Postma MJ, et al. A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Hum Vaccin Immunother 2013;9:11
   Google Scholar
• EMA/CHMP. Assessment Report EMA/653012/2011; 23 June 2011. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000703/WC500118054.pdf [Last accessed October 2013]
   Google Scholar
• Korostil IA, Ali H, Guy RJ, et al. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013;40(11):833-5
   PubMed Web of Science ®Google Scholar
• Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013;13:140
   PubMed Web of Science ®Google Scholar
• Bottiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 1997;15(14):1538-44
   PubMed Web of Science ®Google Scholar
• Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol 2010;117(2 Suppl):S26-31
   PubMed Web of Science ®Google Scholar
• Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 1997;314(7086):1033-6
   PubMed Web of Science ®Google Scholar